Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 9
Submit an article Journal homepage
30
Views
20
CrossRef citations to date
0
Altmetric
Review

Recent advances in antitrypanosomal chemotherapy: patent literature 2002 – 2004

Christophe Dardonville Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain. [email protected]
Pages 1241-1257 | Published online: 02 Dec 2005

Bibliography

  • BARRETT MP, BURCHMORE RJ,STICH A et al.: The trypanosomiases. Lancet (2003) 362(9394):1469–1480. This review gives an excellent overview of Chagas disease and sleeping sickness with emphasis on similarities and divergencies between T cruzi and T brucei.
  • African trypanosomiasis — WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. (2000).
  • URBINA JA: Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. (2001) 14(6):733–741.
  • URBINA JA: Chemotherapy of Chagas disease. Curr. Pharm. Des. (2002) 8(4):287–295.
  • URBINA JA, DOCAMPO R: Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol (2003) 19(11):495–501.
  • BURCHMORE RJ, OGBUNUDE PO, ENANGA B, BARRETT MP: Chemotherapy of human African trypanosomiasis. Curr Pharm. Des. (2002) 8(4):256–267.
  • KEISER J, STICH A. BURRI C: New drugs for the treatment of human African trypanosomiasis: research and development. Trends Parasitol (2001) 17:42–49.
  • FAIRIAMB AH: Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol (2003) 19(11):488–494.
  • DE KONING HP: Transporters in Africantrypanosomes: role in drug action and resistance. Int. J. Parasitol. (2001) 31:512–522.
  • DENISE H, BARRETT MP: Uptake and mode of action of drugs used against sleeping sickness. Biochem. Pharmacol. (2001) 61:1–5.
  • MANSOUR T: Chemotherapeutic targets in parasites: contemporary strategies. Cambridge University Press (2002):90–122.
  • LAKHDAR-GHAZAL F, BLONSKI C, WILLSON M, MICHELS P, PERIE J: Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr. Top. Med. Chem. (2002) 2(5):439–456.
  • VERLINDE CL, HANNAERT BLONSKI C et al.: Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resist. Updeit. (2001) 4(1):50–65.
  • HANAU S, RINALDI E, DALLOCCHIO F et al.: 6-Phosphogluconate dehydrogenase: a target for drugs in African trypanosomes. Curr. Med. Chem. (2004) 11(19):2639–2650.
  • DARDONVILLE C, RINALDI E, BARRETT MP et al.: Selective inhibition ofTrypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues. J. Med. Chem. (2004) 47(13):3427–3437.
  • DARDONVILLE C, RINALDI E, HANAU S et al.: Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg. Med. Chem. (2003) 11(14):3205–3214.
  • SCHMIDT A, KRAUTH-SIEGEL RL: Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr. Top. Med. Chem. (2002) 2(11):1239–1259.
  • AUGUSTYNS K, AMSSOMS K, YAMANI A, RAJAN PK, HAEMERS A: Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr. Pharm. Des. (2001) 7(12):1117–1141.
  • MULLER S, COOMBS GH, WALTER RD: Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. (2001) 17(5):242–249.
  • DETERDING A. DUNGEY FA, THOMPSON KA, STEVERDING D: Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. (2005) 93(3):311–316.
  • DAS A, DASGUPTA A, SENGUPTA T, MAJUMDER HK: Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol. (2004) 20(8):381–387.
  • ANSEDE JH, ANBAZHAGAN M, BRUIN R et al.: 0-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. (2004) 47(17):4335–4338.
  • ZHOU L, VOYKSNER RD, THAKKER DR et al.: Characterizing the fragmentation of 2,5-bis (4-amidinophenyl)fitran-bis-0-methylamidoxime and selected metabolites using ion trap mass spectrometry. Rapid Commun. Mass Spectrom. (2002) 16(10:1078–1085.
  • ZHOU L, THAKKER D, VOYKSNER R et al.: In vitro metabolism of a novel antimicrobial prodrug 2,5-bis(4-amidinephenypfuran-bis-0-methylamidoxime. FASEB J. (2002) 16(4):A561–A561.
  • URBINA JA: New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin. Ther. Patents (2003) 13(5):661–669.
  • CAZZULO JJ: Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Chagas desease. Cuff. Top. Med. Chem. (2002) 2(11):1261–1271.
  • CAFFREY CR, SCORY S, STEVERDING D: Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets (2000) 1(2):155–162.
  • CAZZULO JJ, STOKA V, TURK V: The major cysteine proteinase of Trypanosoma cruzi: A valid target for chemotherapy of Chagas disease. Curr. Pharm. Des. (2001) 7(12):1143–1156.
  • TROEBERG L, MORTY RE, PIKE RN et al.: Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp. Parasitol. (1999) 91(0349–355.
  • ENGEL JC, DOYLE PS, HSIEH I, MCKERROW JH: Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. (1998) 188(4):725–734.
  • SCORY S, CAFFREY CR, STIERHOF YD, RUPPELA, STEVERDING D: Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. Exp. Parasita (1999) 91(0327–333.
  • MCGRATH ME, EAKIN AE, ENGEL JC et al.: The crystal structure of cruzain: a therapeutic target for Chagas' disease. Mo/. Bid. (1995) 247(2):251–259.
  • SCHEIDT KA, ROUSH WR, MCKERROW JH et al.: Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg. Med. Chem. (1998) 6(12):2477–2494.
  • BRINEN LS, HANSELL E, CHENG J et al.: A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. Structure Fold Des. (2000) 8(8):831–840.
  • HUANG L, BRINEN LS, ELLMAN JA: Crystal structures of reversible ketone-based inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. (2003) 11(1):21–29.
  • MOTTRAM JC, NORTH MJ, BARRY JD, COOMBS GH: A cysteine proteinase cDNA from Trypanosoma brucei predicts an enzyme with an unusual C-terminal extension. FEBS Lett. (1989) 258(2):211–215.
  • EAKIN AE, MILLS AA, HARTH G, MCKERROW JH, CRAIK CS: The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J. Biol. Chem. (1992) 267(10:7411–7420.
  • CAMPETELLA 0, HENRIKSSON J, ASLUND Let al.: The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. MoL Biochem. ParasitoL (1992) 50(2):225–234.
  • CHOE Y, BRINEN LS, PRICE MS et aL: Development of a-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg. Med. Chem. (2005) 13(6):2141–2156.
  • HUANG L, ELLMAN JA: General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett (2002) 12(20):2993–2996.
  • HUANG L, LEE A, ELLMAN JA: Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J. Med. Chem. (2002) 45(3):676–684.
  • FUJII N, MALLARI: JP, HANSELL EJ et al.: Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg. Med. Chem. Lett (2005) 15(1):121–123.
  • DUX, GUO C, HANSELL E et aL: Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. (2002) 45(13):2695–2707.
  • GREENBAUM DC, MACKEY Z, HANSELL E et al.: Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. (2004) 47(12):3212–3219.
  • URBINA JA: Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology (1997) 114(Suppl.):591–S99.
  • URBINA JA, CONCEPCION JL, RANGEL S, VISBAL G, LIRA R: Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasit. (2002) 125(1-2):35–45.
  • URBINA JA, PAYARES G, SANOJA C, LIRA R, ROMANHA AJ: In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. j Antimicrob. Ag (2003) 21(1):27–38.
  • URBINA JA, PAYARES G, SANOJA C et al.: Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Ag (2003) 21(1):39–48.
  • COPPENS I, COURTOY PJ: The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. Ann. Rev Microbiol (2000) 54:129–156.
  • URBINA JA, CONCEPCION JL, MONTALVE1"11 A. RODRIGUEZ JB, DOCAMPO R: Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob. Agents Ch. (2003) 47(6):2047–2050.
  • BRAGA MV URBINA JA, DE SOUZAW: Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents (2004) 24(1):72–78.
  • URBINA JA, CONCEPCION JL, CALDERAA et aL: In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother. (2004) 48(7):2379–2387.
  • ORENES LORENTE S, GOMEZ R, JIMENEZ C et al.: Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg. Med. Chem. (2005) 13:3519–3529.
  • MAGARACI F, JIMENEZ CJ, RODRIGUES C et al.: Azasterols as inhibitors of sterol 24-methyltransferase in leishmania species and Trypanosoma cruzi. J. Med. Chem. (2003) 46(22):4714–4727.
  • MARTIN MB, GRIMLEY JS, LEWIS JC et aL: Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. (2001) 44(6):909–916.
  • LEONARD DM: Ras farnesyltransferase: a new therapeutic target. J. Med. Chem. (1997) 40(19):2971–2990.
  • LOMBARDO LJ, CAMUSO k CLARK J et aL: Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett (2005) 15(7):1895–1899.
  • KARP JE, KAUFMANN SH, ADJEI AA et al.: Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. (2001) 13(6):470–476.
  • GELB MH, VAN VOORHIS WC, BUCKNER FS et aL: Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. MoL Biochem. ParasitoL (2003) 126(2):155–163.
  • •This paper gives evidences supporting the use of protein famesyltransferases inhibitors of trypanosomatid parasites as therapeutic targets.
  • ISMAIL Mk BRUN R, EASTERBROOK JD et aL: Synthesis and antiprotozoal activity of aza-analogues of furamidine. J. Med. Chem. (2003) 46(22):4761–4769.
  • ••This paper reports furamidine derivativeswith excellent in vitro and in vivo activity on T b. rbodesiense. These results refer to the patent application [120].
  • BAILLY C, ARAFA RK, TANIOUS FA et aL: Molecular determinants for DNA minor groove recognition: design of a bis-guanidinium derivative of ethidium that is highly selective for AT-rich DNA sequences. Biochemistry (2005) 44(6):1941–1952.
  • CHARRIS J, CAMACHO J, BARAZARTER A et aL: Synthesis of 2,5-bis-[4-(benzhydrazido)-phenyl]furans and evaluation of the antimalarial, trypanocidal and cytoxic activities. Heterocyd Commun. (2004) 10(2-3):157–162.
  • ISMAIL MA, BRUN R, WENZLER T et al.: Novel dicationic imidazo [1,2-a] pyridines and 5, 6, 7, 8-tetrahydro-imidazo [1,2-a] pyridines as antiprotozoal agents. J. Med. Chem. (2004) 47(103658–3664.
  • ISMAIL MA, BRUN R, WENZLER T et al.: Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg. Med. Chem. (2004) 12(20):5405–5413.
  • MALLENA S, LEE MP, BAILLY C et al.: Thiophene-based diamidine forms a 'super' at binding minor groove agent. J. Am. Chem. Soc. (2004) 126(42):13659–13669.
  • ROWLAND EC, MOORE-LAI D, SEED JR, STEPHENS CE, BOYKIN DW: Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds. J. ParasitoL (2003) 89(5):1078–1080.
  • STEPHENS CE, BRUN R, SALEM MM et al.: The activity of diguanidino and 'reversed' diamidino 2,5-diarylfitrans versus Trypanosoma cruzi and Leishmania donovani. Bioorg. Med. Chem. Lett (2003) 13(12):2065–2069.
  • BRENDLE JJ, OUTLAW A, KUMAR A et al.: Antileishmanial activities of several classes of aromatic dications. Antimicrob Agents Chemother. (2002) 46(3):797–807.
  • FITZGERALD DJ, ANDERSON JN: Selective nucleosome disruption by drugs that bind in the minor groove of DNA. Biol. Chem. (1999) 274(38):27128–27138.
  • BAILLY C, DASSONNEVILLE L, CARRASCO C et al.: Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives. Anticancer Drug Des. (1999) 14(1):47–60.
  • STEPHENS CE, BRUN R, HALL JE, BOYKIN DW: Synthesis and antitrypanosomal activity of novel dicationic 'reversed amidines' in the 2,5-diarylfuran series. Abstr. Pap. Am. Chem. S. (2001) 221:U35–U35.
  • OCHOLA DO, PRICHARD RK, LUBEGA GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J. Parasitol (2002) 88(3):600–604.
  • WERBOVETZ KA, SACKETT DL, DELFIN D et al: Selective antimicrotubule activity of Nl-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites. MoL Pharmacol (2003) 64(6):1325–1333.
  • TRAUB-CSEKO YM, RAMALHO-ORTIGAO JM, DANTAS AP et al.: Dinitroaniline herbicides against protozoan parasites: the case of Trypanosoma cruzi. Trends Parasitol (2001) 17(3):136–141.
  • BHATTACHARYA G, SALEM MM, WERBOVETZ KA: Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin. Bioorg Med. Chem. Lett (2002) 12(17):2395–2398.
  • BHATTACHARYA G, HERMAN J, DELFIN D et al.: Synthesis and antitubulin activity of N1- and N4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania. J. Med. Chem. (2004) 47(7):1823–1832.
  • BERENS R, KRUG E, MARR JJ: Purine and pyrimidine metabolism. In: Biochemistry and Molecular Biology of Parasites. Muller M (Ed.), Academic Press San Diego. (1995):89–118.
  • MARR JJ, BERENS RL, NELSON DJ: Antitrypanosomal effect of allopurinol: conversion in vivo to aminopyrazolopyrimidine nucleotides by Trypanosoma cruzi. Science (1978) 201(4360):1018–1020.
  • MARR JJ: Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med. (1991) 118(2):111–119.
  • STOUT CD: Induced fit, drug design, and dUTPase. Structure (2004) 12(1):2–3.
  • HIDALGO-ZARCO F, GONZALEZ-PAZANOWSKA D: Trypanosomal dUTPases as potential targets for drug design. Curr. Protein Pept. Sci. (2001) 2(4):389–397.
  • WHITTINGHAM JL, LEAL I, NGUYEN C et al.: dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors. Structure (2005) 13(2):329–338.
  • HOFER A. STEVERDING D, CHABES A, BRUN R, THELANDER L: Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness. Proc. Natl Acad. Sci. USA (2001) 98(1 0:6412–6416.
  • BRINGMANN G, HOERR V HOLZGRABE U, STICH A: Antitrypanosomal naphthylisoquinoline alkaloids and related compounds. Pharmazie (2003) 58(5):343–346.
  • HOET S, OPPERDOES F, BRUN R, QUETIN-LECLERCQJ: Natural products active against African trypanosomes: a step towards new drugs. Nat. Prod. Rep. (2004) 21(3):353–364.
  • •A thorough literature review of compounds active against T brucei isolated from natural sources in the last 20 years.
  • BRINGMANN G, MESSER K, WOLF K et al.: Dioncophylline E from Dioncophyllum thollonii, the first 7,3'-coupled dioncophyllaceous naphthylisoquinoline alkaloid. Phytochemistry (2002) 60(4):389–397.
  • BRINGMANN G, RISCHER H, WOHLFARTH M, SCHLAUER J: Biosynthesis of antidesmone in cell cultures of Antidesma membranaceum (Euphorbiaceae): an unprecedented class of glycine-derived alkaloids. J. Am. Chem. Soc. (2000) 122(41):9905–9910.
  • BRINGMANN G, SCHLAUER J, RISCHER H et al.: Revised structure of antidesmone, an unusual alkaloid from tropical Antidesma plants (Euphorbiaceae). Tetrahedron (2000) 56(23):3691–3695.
  • KARDONO LB, ANGERHOFER CK, TSAURI S et al.: Cytotoxic and antimalarial constituents of the roots of Eurycoma longifilia. J. Nat. Prod. (1991) 54(5):1360–1367.
  • FERREIRA ME, ROJAS DE ARIAS A, TORRES DE ORTIZ S et al: Leishmanicidal activity of two canthin-6-one alkaloids, two major constituents of Zanthoxylum chiloperone var. angustifolium. J. Ethnopharmacol (2002) 80(2-3):199–202.
  • BASTOS JK, ALBUQUERQUE S, SILVA ML: Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo. Planta Med. (1999) 65(6):541–544.
  • DE SOUZA VA, DA SILVA R, PEREIRA AC et al.: Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi. Bioorg. Med. Chem. Lett (2005) 15(2):303–307.
  • ANG KK, HOLMES MJ, HIGA T, HAIVIANN MT, KARA UA: In vivo antimalarial activity of the 0-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. (2000) 44(6):1645–1649.
  • NKEMNGU NJ, ROSENKRANZ V, WINK M, STEVERDING D: Antitrypanosomal activities of proteasome inhibitors. Antimicrob. Agents Chemother. (2002) 46(6):2038–2040.
  • WHO -The World Health Report 2002. (2002) World Health Organization
  • TROUILLER P, OLLIARO P, TORREELE E et al: Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 359(9324):2188–2194.
  • BARRETT MP, GILBERT IH: Perspectives for new drugs against trypanosomiasis and leishmaniasis. Cuff. Top. Med. Chem. (2002) 2(5):471–482.
  • DARDONVILLE C, BRUN R: Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation. J. Med. Chem. (2004) 47(9):2296–2307. Patents

Websites

  • http://www.who.int/mediacentre/ factsheets/fs259/en/ WHO - African trypanosomiasis or sleeping sickness.
  • http://www.who.int/ctd/chagas/disease.htm WHO - Chagas.
  • http://www.sti.ch/pdfshreport4.pdf Swiss Tropical Institute Report 2003–2004. Section 4: Parasite Chemotherapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.